Webb8 sep. 2024 · Background: Although the current gold standard for diagnosing thyroid nodule malignancy is ultrasound-guided fine-needle aspiration (FNA) cytology, about 20–25% of cytological evaluations are considered indeterminate for malignancy. This limitation has led to the emergence of next-generation sequencing panels, for example, … Webb10 feb. 2016 · May 16, 2024 updated by: Jonsson Comprehensive Cancer Center The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life.
ThyroSeq v3 for Bethesda III and IV: An institutional experience
WebbBoth the ThyroSeq and Afirma GEC tests demonstrated decreases in the PPV when NIFTP was considered nonmalignant. In the era of NIFTP, a "positive" test result for either the … WebbThyroSeq® testing has been validated for use on a variety of specimen types: ThyroSeq® GC test can be ordered with Thyroid FNA Analysis as all indeterminate FNA results are reflexed to ThyroSeq®. ThyroSeq® GC test can be ordered independently after FNA analysis is performed at your local cytopathology laboratory. jeri craden
Molecular testing for thyroid nodules: Review and current state
Webb27 feb. 2024 · ThyroSeq (which stands for “ Thyro id Seq uencing”) represents one of the molecular approaches to thyroid nodules that is based on the detection of thyroid cancer–associated molecular alterations in cell DNA and RNA. Webb21 sep. 2024 · Thyroseq is in its 3rd version and analyzes the sample for known DNA and RNA alterations that are markers of benign or possibly malignant lesions. This test has a … WebbThe primary goal of thyroid nodule evaluation is to determine whether it is malignant. After thyroid ultrasonography has been performed, the next step is measurement of serum … lamb ametek company